PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28280092-4 2017 Enzalutamide is a strong cytochrome P450 3A4 (CYP3A4) inducer, and ETs are commonly metabolized by CYP3A4. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-44 32548867-3 2020 Enzalutamide, a CYP3A4 inducer, at a standard dose of 160 mg reduces the exposure of sorafenib, a CYP3A4 substrate. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 16-22 32548867-3 2020 Enzalutamide, a CYP3A4 inducer, at a standard dose of 160 mg reduces the exposure of sorafenib, a CYP3A4 substrate. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 98-104 31630979-2 2020 ENZA is extensively metabolized by cytochrome P450 3A4 into N-desmethyl ENZA (NDE), an active metabolite. enzalutamide 0-4 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-54 31630979-2 2020 ENZA is extensively metabolized by cytochrome P450 3A4 into N-desmethyl ENZA (NDE), an active metabolite. enzalutamide 72-76 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-54 30319126-6 2018 Enzalutamide is rapidly metabolized by the liver, mainly through the CYP2C8 and to a lesser extent by CYP3A4/5 so that its metabolism may be altered when cytochrome isoenzyme inductor or inhibitor drugs are given concomitantly. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 102-108 30319126-7 2018 Moreover, enzalutamide may require dose adjustment for other drugs since it is a potent inductor of CYP3A4 and a moderate inductor of CYP2C9 y el CYP2C19. enzalutamide 10-22 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 100-106 28280092-4 2017 Enzalutamide is a strong cytochrome P450 3A4 (CYP3A4) inducer, and ETs are commonly metabolized by CYP3A4. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 46-52 26927871-6 2016 Hence enzalutamide, a strong Cyp3A4 inductor, has the potential to substantially decrease plasma concentrations and the effects of many co-medications in this patient population, whereas abiraterone acetate, a strong Cyp2D6 inhibitor, is less of a concern with respect to Cyp450 inhibition, since the Cyp2D6-mediated metabolism is much smaller and Cyp2D6 substrates are prescribed to a lesser extent in patients with prostate cancer. enzalutamide 6-18 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 28340451-7 2017 Enzalutamide may decrease plasma levels of CYP3A4, 2C9 and 2C19 substrates including disopiramide, quetiapine, quinidine and warfarin. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-49 25929560-6 2015 Enzalutamide reduced the AUC of oral S-warfarin, omeprazole, and midazolam by 56, 70, and 86 %, respectively; therefore, enzalutamide is a moderate inducer of CYP2C9 and CYP2C19 and a strong inducer of CYP3A4. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 203-209 27604990-0 2016 Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide. enzalutamide 95-107 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-71 27604990-7 2016 Enzalutamide is a potent CYP3A inducer and a model-based approach to guide dose-selection for enzalutamide combinations that are CYP3A substrates is needed. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-30 27604990-7 2016 Enzalutamide is a potent CYP3A inducer and a model-based approach to guide dose-selection for enzalutamide combinations that are CYP3A substrates is needed. enzalutamide 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 129-134 27604990-7 2016 Enzalutamide is a potent CYP3A inducer and a model-based approach to guide dose-selection for enzalutamide combinations that are CYP3A substrates is needed. enzalutamide 94-106 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 129-134 27604990-8 2016 OBJECTIVE: A "fit for purpose" PBPK model of enzalutamide was developed to illustrate the CYP3A4 induction potential, understand the kinetics of de-induction of CYP3A4 following cessation of enzalutamide dosing and guide dose-selection of a co-administered CYP3A substrate. enzalutamide 45-57 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 90-96 27604990-8 2016 OBJECTIVE: A "fit for purpose" PBPK model of enzalutamide was developed to illustrate the CYP3A4 induction potential, understand the kinetics of de-induction of CYP3A4 following cessation of enzalutamide dosing and guide dose-selection of a co-administered CYP3A substrate. enzalutamide 45-57 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 161-167 27604990-8 2016 OBJECTIVE: A "fit for purpose" PBPK model of enzalutamide was developed to illustrate the CYP3A4 induction potential, understand the kinetics of de-induction of CYP3A4 following cessation of enzalutamide dosing and guide dose-selection of a co-administered CYP3A substrate. enzalutamide 45-57 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 90-95 27604990-13 2016 Model application was demonstrated by simulating a drug-drug interaction between enzalutamide and midazolam, a sensitive CYP3A4 substrate. enzalutamide 81-93 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 121-127 27604990-15 2016 Based on modeling, upon cessation of enzalutamide dosing, it is predicted that at least 8 weeks are needed to re-attain baseline CYP3A4 activity. enzalutamide 37-49 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 129-135 27604990-17 2016 CONCLUSION: A "fit for purpose" PBPK model of enzalutamide was successfully developed using public information that recapitulated it"s observed pharmacokinetics, CYP3A4 induction potential and the potential need for dose-adjustment of co-administered CYP3A substrates. enzalutamide 46-58 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 162-168 27604990-17 2016 CONCLUSION: A "fit for purpose" PBPK model of enzalutamide was successfully developed using public information that recapitulated it"s observed pharmacokinetics, CYP3A4 induction potential and the potential need for dose-adjustment of co-administered CYP3A substrates. enzalutamide 46-58 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 162-167 25929560-6 2015 Enzalutamide reduced the AUC of oral S-warfarin, omeprazole, and midazolam by 56, 70, and 86 %, respectively; therefore, enzalutamide is a moderate inducer of CYP2C9 and CYP2C19 and a strong inducer of CYP3A4. enzalutamide 122-134 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 203-209 25929560-8 2015 It is recommended to avoid concomitant use of enzalutamide with narrow therapeutic index drugs metabolized by CYP2C9, CYP2C19, or CYP3A4, as enzalutamide may decrease their exposure. enzalutamide 46-58 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 130-136 25929560-8 2015 It is recommended to avoid concomitant use of enzalutamide with narrow therapeutic index drugs metabolized by CYP2C9, CYP2C19, or CYP3A4, as enzalutamide may decrease their exposure. enzalutamide 141-153 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 130-136